Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Melanoma 5Leukemia 5Prostatic Neoplasms 3Lymphoma 3Sarcoma 2Ovarian Neoplasms 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Myelodysplastic Syndromes 1

Interventions

Sodium Chloride 2Paclitaxel 2Oxaliplatin 2Folfox protocol 2Carboplatin 2Taxes 1Saline Solution 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Pharmacogenomic Testing 1Leucovorin 1Gene Expression Profiling 1Fluorouracil 1Brachytherapy 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neurotoxicity Syndromes × Gene Expression Profiling × Clear all
NCT00884767 2009-07-08

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

National Cancer Institute (NCI)

Phase 2 Unknown
206 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡